- Home
- DAWN vs CBRE Comparison
DAWN vs CBRE Comparison
Compare DAWN & CBRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- CBRE
- Stock Information
- Founded
- DAWN 2018
- CBRE 1906
- Country
- DAWN United States
- CBRE United States
- Employees
- DAWN N/A
- CBRE N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- CBRE Real Estate
- Sector
- DAWN Health Care
- CBRE Finance
- Exchange
- DAWN Nasdaq
- CBRE Nasdaq
- Market Cap
- DAWN 624.8M
- CBRE 47.3B
- IPO Year
- DAWN 2021
- CBRE 2004
- Fundamental
- Price
- DAWN $7.11
- CBRE $162.93
- Analyst Decision
- DAWN Strong Buy
- CBRE Buy
- Analyst Count
- DAWN 7
- CBRE 9
- Target Price
- DAWN $27.86
- CBRE $165.22
- AVG Volume (30 Days)
- DAWN 960.1K
- CBRE 1.5M
- Earning Date
- DAWN 10-29-2025
- CBRE 10-23-2025
- Dividend Yield
- DAWN N/A
- CBRE N/A
- EPS Growth
- DAWN N/A
- CBRE 19.77
- EPS
- DAWN N/A
- CBRE 3.57
- Revenue
- DAWN $187,638,000.00
- CBRE $38,104,000,000.00
- Revenue This Year
- DAWN $12.56
- CBRE $14.30
- Revenue Next Year
- DAWN $48.02
- CBRE $10.11
- P/E Ratio
- DAWN N/A
- CBRE $45.61
- Revenue Growth
- DAWN 2190.50
- CBRE 14.96
- 52 Week Low
- DAWN $5.64
- CBRE $108.45
- 52 Week High
- DAWN $16.76
- CBRE $167.56
- Technical
- Relative Strength Index (RSI)
- DAWN 51.59
- CBRE 52.19
- Support Level
- DAWN N/A
- CBRE N/A
- Resistance Level
- DAWN $7.58
- CBRE $167.56
- Average True Range (ATR)
- DAWN 0.25
- CBRE 2.48
- MACD
- DAWN -0.32
- CBRE -6.44
- Stochastic Oscillator
- DAWN 91.92
- CBRE 97.24
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.